LYRA:NASDAQLyra Therapeutics, Inc. Analysis

Lyra Therapeutics is confronting a critical corporate crisis: it announced a voluntary Form 25 filing to delist from Nasdaq and its shares were suspended on March 17 2026, creating an imminent risk of loss of public market access. Technically, the stock trades at $0.70, below its 20‑day SMA ($0.717) and far under the 200‑day SMA ($3.21), with a bearish MACD histogram (-0.003) and a neutral‑to‑bearish RSI (48), while volume is shrinking and 30‑day volatility spikes above 90%, indicating a fragile price environment.
Fundamentally, LYRA’s financial picture is dire: revenue has collapsed by 96.7%, gross margin is deeply negative (-152 %), operating loss exceeds $29 M, EPS is –$18.62, cash ($15.9 M) is dwarfed by debt ($30.3 M), and book value per share sits at –$6.04. The company reports no dividend, a negative PE and PB, and a max drawdown of –98 %, underscoring the absence of sustainable earnings or asset value.